Navigation Links
Innervator NS252

ProductsInnervator NS252
Company Fisher & Paykel Healthcare
Item Innervator NS252
Features 
  • Fully programmable peripheral nerve stimulator
  • Offers conventional stimulation patterns and more
  • Post Tetanic Count stimulation pattern for monitoring during sleep relaxation
  • Double Burst stimulation for pattern for assessing residual blocking agent
    • Description The Innervator252 is a fully featured programmable peripheral nerve stimulator offering just not the conventional stimulation patterns i.e. Single Twitch, Train of Four, or Tetanus, but also has available Post Tetanic Count and Double Burst Stimulation.

    The constant current NS232, NS252, NS272 PNS are the only known PNS that can be programmed. Hand-held, battery operated, and includes automatically repeating stimulation patterns.
    Info Fisher & Paykel Healthcare
    Customer Service: (800) 446-3908
    Web site: http://www.fphcare.com

    Related medicine products :

    1. Innervator NS232
    2. Innervator NS242
    3. Innervator NS272
    ...oratories is a national reference laboratory and a...h and development. ARUP offers an extensive test m...clinical and anatomic pathology. Owned by the Univ... more than half of the nation's university teachin...
    ...oratories is a national reference laboratory and a...h and development. ARUP offers an extensive test m...clinical and anatomic pathology. Owned by the Univ... more than half of the nation's university teachin...
    ...oratories is a national reference laboratory and a...h and development. ARUP offers an extensive test m...clinical and anatomic pathology. Owned by the Univ... more than half of the nation's university teachin...
    ...oratories is a national reference laboratory and a...h and development. ARUP offers an extensive test m...clinical and anatomic pathology. Owned by the Univ... more than half of the nation's university teachin...
    Medicine Products:
    (Date:10/10/2008)...Michigan received $5 million from the National Ins...esource of high-quality experimental data sets of ...mputer-aided drug design to a new level. , The ...puter programs that can predict the effectiveness ...ciate professor in the U-M College of Pharmacy and...
    (Date:10/10/2008)... Johns Hopkins University School,of Medicine is la...ptimizing Adjuvant Breast Cancer Strategies: From ...ent key research data on the latest advances in,br...ents in the treatment of breast cancer have,led to...ons that are,increasingly tailored to the specific...
    (Date:10/10/2008)... The Mobile Massage Team, (http://www.mobilemassag...massage,services for corporate wellness programs, ... today that it is expanding its service area throu...lphia metropolitan region., "We are quite excited...ed, massage programs and services throughout both...
    (Date:10/10/2008)...nationally recognized faculty will,present the ver...east,cancer in the multimedia course "Optimizing A...to Treatment Selection" during National Breast,Can...icing oncologists and other interested,health care...t care,advances. This accredited course offers con...
    Breaking Medicine News(10 mins):Health News:U-M to house leading drug database 2Health News:Latest Research on Breast Cancer Presented in a Virtual E-Conference CME Course 2Health News:Mobile Massage Team Announces Expansion of On-Site Seated Massage Services Throughout Eastern Pennsylvania and the Greater Philadelphia Region 2Health News:Nationally Recognized Faculty Presents Latest Advances in Care of Patients with Breast Cancer 2
    ...und out that swimming helps immensely the children...on-swimmers. // Researches conducted over six yea...munities in western Australia's Pilbara region exa...health where swimming pools were installed, report...
    ...rs at the U.S. military prison in Guantanamo Bay t...rike) through insertion of feeding tubes // throug...al associations and ethicists, who claim that such...nciples of medical ethics. In addition, the priso...
    ... expert has warned against indiscriminate antibiot...ustralians use ,are prescribed inappropriately. //...n Society for Antimicrobials annual scientific dis...t John Turnidge, of the Adelaide Women's and Child...
    ...fered insights into why Africans have an increased...nifestation of the disease compared to whites. //...le are afflicted with TB and over 2 million people...aused by Mycobacterium tuberculosis. According to ...
    Other Medicine News:Health News:Medical Ethics Violated By Prison Officials In Guantanamo Bay 2Health News:Vitamin D May Help In Fight Against Tuberculosis 2
    (Date:10/8/2008)...ew Zanolimumab Program to be Discontinued and Head... Results of its Portfolio Review; Zanolimumab Pro...e the Number of Empl...l/ -- Genmab A/S (OMX: GEN),announced today that i...ax-CD4(R)). In addition, as a result of a portfoli...
    (Date:10/8/2008)...US clinical program to evaluate TAXUS(R) Element(T... Stent, NATICK, Mass., Oct. 8 /PRNewswire-First... ) today announced that it has completed enrollmen...ompany,s third-generation,TAXUS(R) Element(TM) pac...al program has enrolled nearly 1,500 patients at 1...
    (Date:10/8/2008)...YON, France, Oct. 8 /- Vical Incorpor... clinical data and new nonclinical data,demonstrat...e broadly,applicable in DNA- and protein-based inf...vaccines. Alain P. Rolland, Pharm.D., Ph.D., Vical...ill present the data today,Wednesday, October 8, ...
    (Date:10/7/2008)...AN DIEGO, Oct. 7 /- Prometheus Labora...oday announced findings from its,development of PR...od test,for irritable bowel syndrome (IBS). The fi...ssion of particular biomarkers in blood samples,be... of these biomarkers,combined with a proprietary ...
    Breaking Medicine Technology:Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 2Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 3Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 4Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 2Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 3Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 2Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 3STERIS Corporation Names Michael J Tokich Chief Financial Officer 14384 1STERIS Corporation Names Michael J Tokich Chief Financial Officer 14384 2STERIS Corporation Names Michael J Tokich Chief Financial Officer 14384 3STERIS Corporation Names Michael J Tokich Chief Financial Officer 14384 4VaxGen Common Stock Now Quoted on OTC Bulletin Board 3971 1VaxGen Common Stock Now Quoted on OTC Bulletin Board 3971 2VaxGen Common Stock Now Quoted on OTC Bulletin Board 3971 3VaxGen Common Stock Now Quoted on OTC Bulletin Board 3971 4Isolagen Inc Completes Enrollment in Isolagen Therapy 28TM 29 Phase II III Acne Scar Study 1520 1Isolagen Inc Completes Enrollment in Isolagen Therapy 28TM 29 Phase II III Acne Scar Study 1520 2Isolagen Inc Completes Enrollment in Isolagen Therapy 28TM 29 Phase II III Acne Scar Study 1520 3Legal exposure to asbestos like material linked to lung damage 25 years later 14381 1Legal exposure to asbestos like material linked to lung damage 25 years later 14381 2Legal exposure to asbestos like material linked to lung damage 25 years later 14381 3
    ...BUSINESS WIRE)--Jun 5, 2007 - Gloucester,Pharmaceu...,development company, today announced that data fo...ymphoma (CTCL) and peripheral,T-cell lymphoma (PTC...cal Oncology (ASCO) Annual Meeting being held in C...rim analysis of a phase II,study of romidepsin spo...
    ...how Antibodies Against Cancer-Causing Virus,Types ...an Natural,Infection Levels, CHICAGO, June 05, 200...18 months after the first of a three-dose regimen,... the GlaxoSmithKline,(GSK) cervical cancer candida...most common cancer-causing human papillomavirus,ty...
    Other Medicine Technology:Gloucester Pharmaceuticals Reports Positive Interim Phase II Data,on Romidepsin for T-Cell Lymphomas at the 2007 American Society of,Clinical Oncology Annual Meeting 2Gloucester Pharmaceuticals Reports Positive Interim Phase II Data,on Romidepsin for T-Cell Lymphomas at the 2007 American Society of,Clinical Oncology Annual Meeting 3Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides,Sustained Immune Response in 100 Percent of Women up to 55 Years of,Age 2Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides,Sustained Immune Response in 100 Percent of Women up to 55 Years of,Age 3Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides,Sustained Immune Response in 100 Percent of Women up to 55 Years of,Age 4Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides,Sustained Immune Response in 100 Percent of Women up to 55 Years of,Age 5